UK-based GW Pharmaceuticals’ Epidiolex looks on course for approval in the US, after a panel of FDA experts unanimously backed it as a treatment for two rare forms of epilepsy. The FDA's ...

GW Pharma is to begin phase 3 trials of its epilepsy drug Epidiolex (cannabidiol) as an adjunctive therapy for the rare disease Tuberous Sclerosis Complex, following its recent late stage success ...